-
SciClone Pharmaceuticals’ Vaborem IND Filing Accepted by NMPA
•
SciClone Pharmaceuticals Inc (HKG: 6600) has announced that an Investigational New Drug (IND) filing for its Vaborem (meropenem vaborbactam), a new antibacterial drug, has been accepted for review by the National Medical Products Administration (NMPA). The IND application covers a Phase III clinical study to evaluate the efficacy and safety…
-
Luye Pharma’s Paliperidone Palmitate Accepted for NMPA Review
•
China-based Luye Pharma Group (HKG: 2186) has announced that the market filing for its paliperidone palmitate extended-release injectable suspension (LY03010) has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication is the treatment of acute and maintenance schizophrenia, with no similar product currently approved for…
-
China Downgrades COVID-19 from Class A to Class B Infectious Disease
•
The National Health Commission (NHC) has issued a notice downgrading COVID-19 from a Class A to Class B infectious disease under China’s Prevention and Treatment of Infectious Diseases Law. This change means that COVID-19 will no longer be included in the quarantinable infectious disease management scope. According to the document,…
-
Carrier Biomed Raises ‘Tens of Millions’ in Series A+ Financing Round
•
Carrier Biomed (Soohow) Co., Ltd, an exosome technology developer based in Suzhou, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. The funding was led by existing investors Qingnuo Capital and Tianjin Qingzhi Technology Partnership, along with Suzhou Industrial Park Science and Technology Innovation Investment…
-
Everest Medicines Launches First Phase of Global mRNA Vaccine Manufacturing Site
•
China-based Everest Medicines (HKG: 1952) has announced the initiation of the operation of the first phase of its global manufacturing site dedicated to mRNA vaccine production in Jiashan, Zhejiang province. The first phase of the project, covering an area of 58,000 square meters and with an investment of more than…
-
InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL
•
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Department of Health in Hong Kong for its tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).…
-
LeadArt Biotechnologies Raises USD 6 Million in Pre-Series A Round
•
LeadArt Biotechnologies Inc., a chemical proteomics specialist based in Ningbo, has reportedly raised close to USD 6 million in a Pre-Series A financing round. The funding was led by Bluerun Ventures, with participation from Yong Chao Venture Capital. The proceeds will be used for the development of a chemical proteomics…
-
Simcere Receives NMPA Clearance for SIM0237 Clinical Study
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products Administration (NMPA) to conduct a clinical study for its SIM0237, an in-house developed bispecific antibody (BsAb) targeting programmed-death ligand 1 (PD-L1) and interleukin-15 (IL-15). The molecule is set for development against locally advanced, unresectable, metastatic…
